Product Program year 2025 Source: CMS Open Payments

Voquezna

Drug Gastroenterology

NDC 81520-100-30

Open in the dashboard

General payments

$14,280,556

112,737 payments

Research payments

$415,247

62 payments

Through program year 2025, $14,280,556 in general payments and $415,247 in research payments were reported against Voquezna (Gastroenterology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $5,053,516 90,356
2025 Research $415,247 62
2024 General $9,199,273 22,285
2023 General $27,766 96

Breakdown

Who paid General payments · program years 2023–2025
  1. Phathom Pharmaceuticals, Inc. $14,280,556 112,737 payments
Top recipients General payments · program year 2025
  1. Asit Parikh Internal Medicine · Boston, MA $184,478 4% · 8 payments
  2. Philip Schoenfeld Gastroenterology · Ann Arbor, MI $117,485 2% · 123 payments
  3. Jonathan Obert Gastroenterology · New Albany, IN $85,496 2% · 91 payments
  4. Daniel Meline Gastroenterology · Scottsdale, AZ $67,482 1% · 105 payments
  5. Rig Patel Gastroenterology · Raleigh, NC $60,747 1% · 43 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Gastroenterology Internal Medicine $2,925,955 59% · 5,046 practitioners
  2. Internal Medicine $519,362 10% · 4,244 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $428,249 9% · 7,253 practitioners
  4. Family Medicine $327,281 7% · 6,646 practitioners
  5. Physician Assistant $232,264 5% · 2,876 practitioners

The top 5 of 162 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $425,189 8% · 2,610 recipients
  2. New York $396,796 8% · 2,470 recipients
  3. Florida $350,625 7% · 2,428 recipients
  4. Illinois $285,746 6% · 1,062 recipients
  5. California $282,005 6% · 2,000 recipients

The top 5 of 54 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

16,241

Prescriptions dispensed, refills included

Drug cost

$12,557,757

Paid at the pharmacy, in all

Prescribers

736

With 11 or more claims of it

Medicare Part D drugs matched to VOQUEZNA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Voquezna Vonoprazan Fumarate Same name 736 16,241 $12,557,757

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Mark Barats Nephrology CA 367 $239,186 $257
Christopher Bui Internal Medicine CA 212 $137,455 $240
Angela Shen Physician Assistant NY 200 $128,457 $509
Annie Chemmanur Gastroenterology MA 192 $128,380 $21,013
Kevin Tin Gastroenterology NY 159 $100,404 $24,897

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
112,737 general · 62 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record